The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM


June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

The agent is approved for PET imaging of PSMA-positive lesions in men with prostate cancer

  • with suspected metastasis who are candidates for initial definitive therapy or
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

“We believe today’s approval is a game-changer for men facing prostate cancer,” said Jamie Bearse, Chief Executive Officer of ZERO – The End of Prostate Cancer, a patient advocacy group. “Having a diagnostic tool that allows doctors to see suspected metastatic or recurrent prostate cancer earlier, anywhere in the body, is a significant step forward and will have a tremendous impact on patients’ lives.”

The agent, initially called 18F-DCFPyL, was developed by Martin Pomper, MD, PhD, director of nuclear medicine and molecular imaging at the Johns Hopkins University School of Medicine. The New Drug Application for the agent was filed in September 2020 and granted priority review by the FDA in December. Research supporting the approval of the agent came from two pivotal multicenter studies—the CONDOR study and the OSPREY study.

The agent is manufactured by Lantheus as Pylarify injection and will be widely available throughout the United States.

For more information: www.snmmi.org

Related Prostate Imaging Agent Information:

PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

For Additional SNMMI21 Content:

SNMMI Channel

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

Total-body Dynamic PET Successfully Detects Metastatic Cancer

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

Related Content

News | Proton Therapy

June 27, 2022 — Varian, a Siemens Healthineers company, announced that the U.S. Food and Drug Administration (FDA) ...

Time June 28, 2022
arrow
News | Radiation Therapy

June 24, 2022 — Recently, a collaborated research team led by Prof. LI Hai and Hongzhi Wang from Hefei Institutes of ...

Time June 24, 2022
arrow
News | Contrast Media

June 23, 2022 — Supply chain disruptions have created critical shortages of Omnipaque (iohexol) and Visipaque (iodixanol ...

Time June 23, 2022
arrow
News | Radiation Therapy

June 23, 2022 — RaySearch Laboratories AB announced the release of the latest version of RayCare*, the next generation ...

Time June 23, 2022
arrow
News | SNMMI

June 22, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear ...

Time June 22, 2022
arrow
News | SNMMI

June 22, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13 ...

Time June 22, 2022
arrow
News | PET Imaging

June 21, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as ...

Time June 21, 2022
arrow
News | SNMMI

June 21, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the ...

Time June 20, 2022
arrow
News | SNMMI

June 16, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at ...

Time June 16, 2022
arrow
News | SPECT Imaging

June 15, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems ...

Time June 15, 2022
arrow
Subscribe Now